Abstract | STUDY OBJECTIVE: To determine the penetration of ceftibuten into various respiratory tissues and fluids. DESIGN: Single-dose, open-label, pharmacokinetic study. SETTING: Veterans Administration Medical Center. PATIENTS: Twelve hospitalized men aged 34 to 75 years with a variety of noninfectious pulmonary symptoms/diseases. INTERVENTIONS: Patients received a single oral dose of ceftibuten, 200 mg, prior to undergoing diagnostic fiberoptic bronchoscopy. Plasma samples for the determination of ceftibuten concentrations were collected pretreatment and up to 12 h postdosing. Nasal secretions, tracheal secretions, BAL fluid, and lung tissue from a biopsy were obtained at bronchoscopy from 2 to 7 h postdosing. MEASUREMENTS AND RESULTS: Mean pharmacokinetic parameters for ceftibuten in plasma were the following: maximum observed plasma concentration (Cmax), 8.77 microg/mL; time to reach Cmax, 2.2 h; area under the plasma concentration-time curve extraploated to infinity, 49.21 microg/h/mL; and terminal elimination half-life, 3.17 h. These parameters were similar to those obtained in studies using healthy volunteers. Mean penetration of ceftibuten into nasal, tracheal, and bronchial secretions was 47%, 50%, and 30%, respectively. Mean penetration into BAL fluid was 81%, whereas penetration into lung tissue was 39%. No patient experienced any adverse effects related to ceftibuten. CONCLUSIONS:
|
Authors | P Krumpe, C C Lin, E Radwanski, M N Cayen, M B Affrime |
Journal | Chest
(Chest)
Vol. 116
Issue 2
Pg. 369-74
(Aug 1999)
ISSN: 0012-3692 [Print] United States |
PMID | 10453864
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Comment)
|
Chemical References |
- Cephalosporins
- Ceftibuten
|
Topics |
- Adult
- Aged
- Bronchoalveolar Lavage Fluid
- Bronchoscopy
- Ceftibuten
- Cephalosporins
(blood, pharmacokinetics)
- Humans
- Male
- Middle Aged
- Respiratory System
(metabolism)
- Respiratory Tract Diseases
(metabolism)
- Tissue Distribution
|